159 related articles for article (PubMed ID: 9763504)
1. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy.
Siegman-Igra Y; Ravona R; Primerman H; Giladi M
Int J Infect Dis; 1998; 2(4):211-5. PubMed ID: 9763504
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
5. Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population.
Smith ZR; Tajchman SK; Dee BM; Bruno JJ; Qiao W; Tverdek FP
J Oncol Pharm Pract; 2016 Jun; 22(3):409-15. PubMed ID: 25956419
[TBL] [Abstract][Full Text] [Related]
6. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.
Chatzinikolaou I; Abi-Said D; Bodey GP; Rolston KV; Tarrand JJ; Samonis G
Arch Intern Med; 2000 Feb; 160(4):501-9. PubMed ID: 10695690
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
[TBL] [Abstract][Full Text] [Related]
8. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies.
Todeschini G; Franchini M; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Murari C; Ricetti MM; Perona G
Int J Infect Dis; 1998-1999 Winter; 3(2):99-104. PubMed ID: 10225988
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.
Vidal F; Mensa J; Almela M; Martínez JA; Marco F; Casals C; Gatell JM; Soriano E; Jimenez de Anta MT
Arch Intern Med; 1996 Oct; 156(18):2121-6. PubMed ID: 8862105
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa bacteremia in patients with AIDS.
Mendelson MH; Gurtman A; Szabo S; Neibart E; Meyers BR; Policar M; Cheung TW; Lillienfeld D; Hammer G; Reddy S
Clin Infect Dis; 1994 Jun; 18(6):886-95. PubMed ID: 8086548
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
Chamot E; Boffi El Amari E; Rohner P; Van Delden C
Antimicrob Agents Chemother; 2003 Sep; 47(9):2756-64. PubMed ID: 12936970
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
[TBL] [Abstract][Full Text] [Related]
13. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies.
Hu Y; Li L; Li W; Xu H; He P; Yan X; Dai H
Int J Antimicrob Agents; 2013 Dec; 42(6):492-6. PubMed ID: 24139926
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
[TBL] [Abstract][Full Text] [Related]
15. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.
Bliziotis IA; Petrosillo N; Michalopoulos A; Samonis G; Falagas ME
PLoS One; 2011; 6(10):e26470. PubMed ID: 22046290
[TBL] [Abstract][Full Text] [Related]
16. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.
Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S
Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor?
Chen SC; Lawrence RH; Byth K; Sorrell TC
Med J Aust; 1993 Nov; 159(9):592-7. PubMed ID: 8232033
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
